Adjuvant chemotherapy for locally advanced bladder cancer

John D. Cant, Maurizio Brausi, Mark S. Soloway

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Although controversy over the relative efficacy of full-dose pelvic radiation and radical cystectomy, with or without pre-operative radiation, continues, none of these treatments directed only at the disease in the pelvis cures more than 50 percent of patients with locally advanced disease. An effective systemic therapy is needed. The most effective single agent in metastatic bladder cancer, Cis-platin, has not altered the cure rate when used as an adjuvant. Limited trials using Cis-platin based three and four drug combination chemotherapy regimens have yielded 50-70 percent overall response rates with 30 percent complete responses in metastatic disease. It seems appropriate to perform pilot studies using these more intensive programs as adjuvant chemotherapy for good performance status patients at high risk of progression, e.g. positive lymph nodes.

Original languageEnglish (US)
Pages (from-to)115-120
Number of pages6
JournalWorld journal of urology
Issue number2
StatePublished - Sep 1 1985

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Adjuvant chemotherapy for locally advanced bladder cancer'. Together they form a unique fingerprint.

Cite this